Wheeler Benjamin J, Taylor Barry J
Department of Women's and Children's Health, University of Otago, Dunedin, 9054, New Zealand.
J Med Case Rep. 2012 Aug 31;6:263. doi: 10.1186/1752-1947-6-263.
Insulin allergy to human insulin preparations during the treatment of diabetes is suggested to occur at rates ranging from <1.0% to 2.4%. These reactions vary from mild localized reactions, which resolve with repeated exposure, to life-threatening anaphylaxis and death. The management of persistent insulin allergy in type 1 diabetes mellitus is particularly complicated because ongoing treatment with insulin is essential.
We present the case of a 12-year-old Caucasian girl with localized allergy to the insulin excipient metacresol, and the subsequent desensitization therapy using continuous subcutaneous insulin infusion with simultaneous intravenous insulin infusion.
This is the first documented case of allergy to the metacresol component of insulin in the pediatric type 1 diabetes literature. We describe an approach to diagnosis and management of metacresol allergy in type 1 diabetes.
糖尿病治疗期间对人胰岛素制剂的胰岛素过敏发生率据报道在<1.0%至2.4%之间。这些反应从轻度局部反应（反复接触后可消退）到危及生命的过敏反应和死亡不等。1型糖尿病中持续性胰岛素过敏的管理尤为复杂，因为持续使用胰岛素治疗至关重要。
我们报告了一名12岁白种女孩对胰岛素辅料间甲酚发生局部过敏的病例，以及随后采用持续皮下胰岛素输注同时静脉输注胰岛素进行脱敏治疗的情况。
这是儿科1型糖尿病文献中首例记录在案的对胰岛素间甲酚成分过敏的病例。我们描述了1型糖尿病中间甲酚过敏的诊断和管理方法。
